{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:54:08Z","timestamp":1774364048880,"version":"3.50.1"},"reference-count":106,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.2515\/therapie:2008059","type":"journal-article","created":{"date-parts":[[2009,1,20]],"date-time":"2009-01-20T13:02:53Z","timestamp":1232456573000},"page":"359-375","source":"Crossref","is-referenced-by-count":6,"title":["Prescription de la risp\u00e9ridone chez l\u2019enfant et l\u2019adolescent"],"prefix":"10.1016","volume":"63","author":[{"given":"Claire","family":"Chevreuil","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Reymann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Fr\u00e9maux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9lisabeth","family":"Polard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanguy","family":"S\u00e9veno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00e8le","family":"Bentu\u00e9-Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie:2008059_bb0010","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0013-7006(05)82409-1","article-title":"Prescription of psychotropic drugs in paediatry: approved indications and therapeutic perspectives","volume":"31","author":"Dumortier","year":"2005","journal-title":"Encephale"},{"key":"10.2515\/therapie:2008059_bb0015","first-page":"188","article-title":"Prescription of olanzapine in children and adolescent psychiatric patients","volume":"33","author":"Fremaux","year":"2007","journal-title":"Encephale"},{"key":"10.2515\/therapie:2008059_bb0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1742-1241.2007.01321.x","article-title":"Paliperidone: quo vadis ?","volume":"61","author":"Citrome","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.2515\/therapie:2008059_bb0025","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2165\/00023210-200519050-00005","article-title":"Risperidone: a review of its use in the treatment of bipolar mania","volume":"19","author":"Fenton","year":"2005","journal-title":"CNS Drugs"},{"key":"10.2515\/therapie:2008059_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/104454604773840472","article-title":"Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications","volume":"14","author":"Gagliano","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0035","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1586\/14737175.5.6.713","article-title":"Risperidone in pervasive developmental diorders","volume":"5","author":"Erickson","year":"2005","journal-title":"Expert Rev Neurother"},{"key":"10.2515\/therapie:2008059_bb0040","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems","volume":"347","author":"McCracken","year":"2002","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie:2008059_bb0045","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"key":"10.2515\/therapie:2008059_bb0050","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology","volume":"162","author":"McDougle","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0055","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/cap.2006.16.575","article-title":"Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy","volume":"16","author":"Luby","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0060","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/00004583-200312000-00011","article-title":"Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials","volume":"42","author":"Arnold","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0065","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months","volume":"162","author":"Research Units on Pediatric Psychopharmacology Autism Network","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0070","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","article-title":"Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study","volume":"44","author":"Troost","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0075","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1097\/00004583-200110000-00015","article-title":"Open trial of risperidone in 24 young children with pervasive developmental disorders","volume":"40","author":"Masi","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0080","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00004583-200202000-00007","article-title":"Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness","volume":"41","author":"Malone","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0011-393X(02)80009-1","article-title":"An open-label trial of risperidone in children with autism","volume":"63","author":"Diler","year":"2002","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.2515\/therapie:2008059_bb0090","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/cap.2000.10.79","article-title":"Long-term risperidone for pervasive developmental disorder: efficacy, tolerability, and discontinuation","volume":"10","author":"Zuddas","year":"2000","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0095","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00004583-199705000-00020","article-title":"Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study","volume":"36","author":"McDougle","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0100","first-page":"155","article-title":"An open clinical trial of risperidone monotherapy in young children with autistic disorder","volume":"33","author":"Findling","year":"1997","journal-title":"Psychopharmacol Bull"},{"key":"10.2515\/therapie:2008059_bb0105","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/00004583-199804000-00014","article-title":"An open trial of risperidone in young autistic children","volume":"37","author":"Nicolson","year":"1998","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/cap.1997.7.167","article-title":"Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up","volume":"7","author":"Perry","year":"1997","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0115","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.4088\/JCP.v64n0909","article-title":"A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone","volume":"64","author":"Masi","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0120","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00148581-200709050-00006","article-title":"Risperidone: a review of its use in the treatment of irritability associated with autistic disorder in children and adolescents","volume":"9","author":"Scott","year":"2007","journal-title":"Paediatr Drugs"},{"key":"10.2515\/therapie:2008059_bb0125","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/00004583-200209000-00002","article-title":"Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs","volume":"41","author":"Snyder","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00004583-200004000-00021","article-title":"A double-blind pilot study of risperidone in the treatment of conduct disorder","volume":"39","author":"Findling","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0135","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1176\/appi.ajp.159.8.1337","article-title":"Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence","volume":"159","author":"Aman","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0140","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/104454601750143348","article-title":"Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial","volume":"11","author":"Van Bellinghen","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0145","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4088\/JCP.v62n0405","article-title":"A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities","volume":"62","author":"Buitelaar","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0150","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1176\/appi.ajp.163.3.402","article-title":"A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders","volume":"163","author":"Reyes","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0155","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1542\/peds.110.3.e34","article-title":"Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs","volume":"110","author":"Turgay","year":"2002","journal-title":"Pediatrics"},{"key":"10.2515\/therapie:2008059_bb0160","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1176\/appi.ajp.161.4.677","article-title":"Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ","volume":"161","author":"Findling","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0165","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.chi.0000145805.24274.09","article-title":"Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients","volume":"44","author":"Croonenberghs","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0170","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00787-006-0504-0","article-title":"Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. Results of a 2-year extension study","volume":"15","author":"Reyes","year":"2006","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0175","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/cap.2000.10.19","article-title":"Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior","volume":"10","author":"Buitelaar","year":"2000","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0180","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/104454602762599880","article-title":"A case series of eight aggressive young children treated with risperidone","volume":"12","author":"Cesena","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0185","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/070674370004500407","article-title":"Inpatient treatment of severe disruptive behaviour disorders with risperidone and milieu therapy","volume":"45","author":"Ad-Dab\u2019bagh","year":"2000","journal-title":"Can J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0190","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/1044546041649020","article-title":"Risperidone effects in the presence\/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ","volume":"14","author":"Aman","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0195","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/chi.0b013e3180323354","article-title":"Risperidone augmentation for treatment-resistant aggression in attention-deficit\/hyperactivity disorder: a placebo-controlled pilot study","volume":"46","author":"Armenteros","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0200","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00148581-200507050-00002","article-title":"Management options for bipolar disorder in children and adolescents","volume":"7","author":"Danielyan","year":"2005","journal-title":"Paediatr Drugs"},{"key":"10.2515\/therapie:2008059_bb0205","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1517\/14656566.8.12.1801","article-title":"Pharmacotherapeutic strategies for pediatric bipolar disorder","volume":"8","author":"Madaan","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.2515\/therapie:2008059_bb0210","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/00004583-199908000-00011","article-title":"Risperidone treatment for juvenile bipolar disorder: a retrospective chart review","volume":"38","author":"Frazier","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0215","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.biopsych.2005.03.019","article-title":"Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children","volume":"58","author":"Biederman","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0220","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1089\/cap.2006.16.336","article-title":"A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder","volume":"16","author":"Pavuluri","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"Suppl 1","key":"10.2515\/therapie:2008059_bb0225","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/j.jad.2004.05.017","article-title":"Open-label prospective trial of risperidone in combination with lithium or divalproex sodium in pediatric mania","volume":"82","author":"Pavuluri","year":"2004","journal-title":"J Affect Disord"},{"key":"10.2515\/therapie:2008059_bb0230","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1399-5618.2006.00334.x","article-title":"Treatment of aggression with risperidone in children and adolescents with bipolar disorder: a case series","volume":"8","author":"Saxena","year":"2006","journal-title":"Bipolar Disord"},{"key":"10.2515\/therapie:2008059_bb0235","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/chi.0b013e318068fbcc","article-title":"Tourette syndrome and tic disorders: a decade of progress","volume":"46","author":"Swain","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0240","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","article-title":"A placebo-controlled trial of risperidone in Tourette syndrome","volume":"60","author":"Scahill","year":"2003","journal-title":"Neurology"},{"key":"10.2515\/therapie:2008059_bb0245","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/00004583-200203000-00013","article-title":"Risperidone versus clonidine in the treatment of children and adolescents with Tourette\u2019s syndrome","volume":"41","author":"Gaffney","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0250","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/00004583-200402000-00017","article-title":"Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial","volume":"43","author":"Gilbert","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0255","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/00004583-199509000-00011","article-title":"Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report","volume":"34","author":"Lombroso","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0260","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1089\/cap.2005.15.318","article-title":"Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea","volume":"15","author":"Kim","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0265","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1157\/13098929","article-title":"Tics in children and adolescents: a retrospective analysis of 78 cases","volume":"66","author":"Catarina Prior","year":"2007","journal-title":"An Pediatr (Barc)"},{"key":"10.2515\/therapie:2008059_bb0270","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.npp.1300327","article-title":"A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial","volume":"29","author":"Sikich","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.2515\/therapie:2008059_bb0275","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00702-002-0803-7","article-title":"Olanzapine, risperidone and haloperidol in the treatment of adolescent patients with schizophrenia","volume":"110","author":"Gothelf","year":"2003","journal-title":"J Neural Transm"},{"key":"10.2515\/therapie:2008059_bb0280","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1089\/cap.2006.16.393","article-title":"An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia","volume":"16","author":"Mozes","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0285","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1089\/104454603322572651","article-title":"Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study","volume":"13","author":"Zalsman","year":"2003","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0290","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/00004583-199705000-00021","article-title":"Risperidone in adolescents with schizophrenia: an open pilot study","volume":"36","author":"Armenteros","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0295","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1097\/00004583-199510000-00014","article-title":"Case study: risperidone in children and adolescents with schizophrenia","volume":"34","author":"Quintana","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"Suppl 1","key":"10.2515\/therapie:2008059_bb0300","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0306-4530(02)00114-2","article-title":"A review of the effect of atypical antipsychotics on weight","volume":"28","author":"Nasrallah","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.2515\/therapie:2008059_bb0305","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/1389450043490514","article-title":"Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics","volume":"5","author":"Baptista","year":"2004","journal-title":"Curr Drug Targets"},{"key":"10.2515\/therapie:2008059_bb0310","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.161.6.1125","article-title":"Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data","volume":"161","author":"Martin","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0315","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.jcp.0000203196.65710.2b","article-title":"Risperidone-related weight gain: genetic and nongenetic predictors","volume":"26","author":"Lane","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0320","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/sj.mp.4001944","article-title":"Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients","volume":"12","author":"Ruano","year":"2007","journal-title":"Mol Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0325","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/10445460152595559","article-title":"Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism","volume":"11","author":"Hellings","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0330","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00004583-200203000-00014","article-title":"Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study","volume":"41","author":"Ratzoni","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0335","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00702-006-0602-7","article-title":"Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents","volume":"114","author":"Fleischhaker","year":"2007","journal-title":"J Neural Transm"},{"key":"10.2515\/therapie:2008059_bb0340","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1089\/cap.1998.8.151","article-title":"Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months","volume":"8","author":"Kelly","year":"1998","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0345","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/cap.2000.10.259","article-title":"Risperidone-associated weight gain in children and adolescents: a retrospective chart review","volume":"10","author":"Martin","year":"2000","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0350","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00787-002-0255-5","article-title":"Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study","volume":"11","author":"Martin","year":"2002","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0355","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00004714-199606000-00017","article-title":"Weight gain associated with risperidone","volume":"16","author":"Penn","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0360","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/104454602760386978","article-title":"Topiramate plus risperidone for controlling weight gain and symptoms in preschool mania","volume":"12","author":"Pavuluri","year":"2002","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0365","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00004583-199705000-00022","article-title":"Case study: risperidone-induced hepatotoxicity in pediatric patients","volume":"36","author":"Kumra","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0370","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1089\/cap.2005.15.869","article-title":"Acute and long-term safety and tolerability of risperidone in children with autism","volume":"15","author":"Aman","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0375","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1089\/cap.2006.16.260","article-title":"Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability","volume":"16","author":"Reyes","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0380","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/000992280404300504","article-title":"Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders","volume":"43","author":"Lindsay","year":"2004","journal-title":"Clin Pediatr (Phila)"},{"key":"10.2515\/therapie:2008059_bb0385","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0390","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1176\/ajp.2006.163.12.2072","article-title":"A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents","volume":"163","author":"Klein","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0395","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","article-title":"Metabolic side effects of antipsychotic medication","volume":"61","author":"Tschoner","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.2515\/therapie:2008059_bb0400","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1176\/appi.ajp.159.4.561","article-title":"Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia","volume":"159","author":"Sernyak","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0405","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00787-006-0580-1","article-title":"Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials","volume":"16","author":"Jensen","year":"2007","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0410","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1542\/peds.113.2.421","article-title":"Risperidone-associated diabetes mellitus in children","volume":"113","author":"Koller","year":"2004","journal-title":"Pediatrics"},{"key":"10.2515\/therapie:2008059_bb0415","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2165\/00002018-200730070-00002","article-title":"Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study","volume":"30","author":"Harrison-Woolrych","year":"2007","journal-title":"Drug Saf"},{"key":"10.2515\/therapie:2008059_bb0420","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1055\/s-2003-43045","article-title":"Risperidone-associated steatohepatitis and excessive weight-gain","volume":"36","author":"Holtmann","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"10.2515\/therapie:2008059_bb0425","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1089\/cap.1999.9.93","article-title":"Risperidone-induced hepato-toxicity in children and adolescents? A chart review study","volume":"9","author":"Szigethy","year":"1999","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0430","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2165\/00023210-200216010-00003","article-title":"Effects of newer antipsychotics on ex-trapyramidal function","volume":"16","author":"Tarsy","year":"2002","journal-title":"CNS Drugs"},{"key":"10.2515\/therapie:2008059_bb0435","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00004583-199903000-00005","article-title":"Risperdal and parkinsonian tremor","volume":"38","author":"Roberts","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0440","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1097\/00004583-199611000-00006","article-title":"Risperidone and tardive dyskinesia","volume":"35","author":"Feeney","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0445","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0450","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/cap.2006.0117","article-title":"One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review","volume":"17","author":"Correll","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0455","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1176\/appi.ajp.158.11.1774","article-title":"Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death","volume":"158","author":"Glassman","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0460","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0465","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4088\/PCC.v05n0504","article-title":"New Generation antipsychotic drugs and QTc interval prolongation","volume":"5","author":"Vieweg","year":"2003","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0470","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/cap.1999.9.273","article-title":"Risperidone in the treatment of two very young children with autism","volume":"9","author":"Posey","year":"1999","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0475","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/cap.2007.0061","article-title":"QT interval and dispersion in very young children treated with antipsychotic drugs: a retrospective chart review","volume":"17","author":"Nahshoni","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0480","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/hup.811","article-title":"Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite","volume":"21","author":"Melkersson","year":"2006","journal-title":"Hum Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0485","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1176\/appi.ajp.162.5.1010","article-title":"Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels","volume":"162","author":"Knegtering","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0490","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/JCP.0b013e31802e68d5","article-title":"Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism","volume":"27","author":"Troost","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0495","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4088\/JCP.v64n1113","article-title":"Prolactin levels during long-term risperidone treatment in children and adolescents","volume":"64","author":"Findling","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0500","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1176\/appi.ajp.161.5.918","article-title":"Growth and sexual maturation during long-term treatment with risperidone","volume":"161","author":"Dunbar","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0505","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.biopsych.2006.02.032","article-title":"Effects of short- and long-term risperidone treatment on prolactin levels in children with autism","volume":"61","author":"Anderson","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0510","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/cap.2005.15.885","article-title":"Risperidone-induced pro-lactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders","volume":"15","author":"Hellings","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0515","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/104454601317261564","article-title":"Prolactin levels in young children with pervasive developmental disorders during risperidone treatment","volume":"11","author":"Masi","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0520","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/00004583-199607000-00006","article-title":"Enuresis with combined risperidone and SSRI use","volume":"35","author":"Took","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0525","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/cap.2006.0056","article-title":"Risperidone-induced enuresis in two children with autistic disorder","volume":"17","author":"Herguner","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.2515\/therapie:2008059_bb0530","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00004583-199902000-00018","article-title":"Neuroleptic malignant syndrome in children and adolescents","volume":"38","author":"Silva","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.2515\/therapie:2008059_bb0535","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1358\/dot.2003.39.7.799445","article-title":"Antipsychotic medication and seizures: a review","volume":"39","author":"Hedges","year":"2003","journal-title":"Drugs Today (Barc)"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716305753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716305753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T08:33:30Z","timestamp":1709973210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716305753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":106,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0040595716305753"],"URL":"https:\/\/doi.org\/10.2515\/therapie:2008059","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}